🔗 Visit the ClinicalTrials.gov page for NCT01359397
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Trial watch: Chemotherapy with immunogenic cell death inducers. | Oncoimmunology | 2012 | 1.33 |
| 2 | Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. | Therap Adv Gastroenterol | 2012 | 0.83 |
| 3 | Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. | World J Gastroenterol | 2013 | 0.82 |
| 4 | New advances in targeted gastric cancer treatment. | World J Gastroenterol | 2016 | 0.81 |
| 5 | Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. | BMC Cancer | 2016 | 0.79 |